[Blood transfusion in surgery: can it still be reduced by human recombinant erythropoietin?].
New agents such as recombinant human erythropoietin (rHu EPO) modify conventional transfusionnal strategies. For accurate indications, such as, anaemia associated with chronic renal failure, cancer or cardiac disease, the preoperative prescription of rHu EPO may reduce transfusion requirements. rHu EPO may also be associated with pre-deposit transfusion in patients with anaemia before blood donation, when the transfusion needs are high, or the period for blood pre-deposit donation shortened. Postoperatively rHu EPO is only efficient if it is administered for a prolonged period; this condition limits its indications and value because of its high cost.
Janvier
G
G
Service d'anesthésie-réanimation chirurgicale II, groupe hospitalier Sud. CHU de Bordeaux, Pessac, France.
Roth
C
C
Bénillan
N
N
Fialon
P
P
Berty
A
A
Puntous
M
M
D007611:Aprotinin / Q000008:administration & dosage; D001803:Blood Transfusion / Q000191:economics / Q000379:methods*; D017558:Elective Surgical Procedures; D004921:Erythropoietin / Q000627:therapeutic use*; D006490:Hemostatics / Q000008:administration & dosage; D006801:Humans; D010952:Plasma Substitutes / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D011300:Preoperative Care / Q000379:methods; D011994:Recombinant Proteins
D006490:Hemostatics; D010952:Plasma Substitutes; D011994:Recombinant Proteins; D004921:Erythropoietin; D007611:Aprotinin
Transfusions en chirurgie: peuvent-elles encore être réduites par l'érythropoïétine humaine recombinante?